首页 | 本学科首页   官方微博 | 高级检索  
     

低剂量替格瑞洛治疗稳定型冠心病患者的疗效及安全性评价
引用本文:李康博 刘晓坤 张琦 韩全乐. 低剂量替格瑞洛治疗稳定型冠心病患者的疗效及安全性评价[J]. 复旦学报(医学版), 2016, 43(2): 164. DOI: 10.3969/j.issn.1672-8467.2016.02.007
作者姓名:李康博 刘晓坤 张琦 韩全乐
作者单位:华北理工大学附属唐山工人医院心血管科 唐山 063000
基金项目:唐山市科技计划项目(13130258a)
摘    要: 目的  评价低剂量替格瑞洛治疗稳定型冠心病 (stable coronary artery disease,SCAD)患者的疗效及安全性。方法  采用随机平行对照的方法入选SCAD患者413例,分别给予替格瑞洛60 mg/次、2次/日 (n=192)或氯吡格雷50 mg/次、1次/日 (n=221),两组均联合应用阿司匹林100 mg/次、1次/日,疗程12个月。采用3种检测方法多时点评价两组患者的血小板功能;比较两组患者的心血管死亡、非致死性心肌梗死、卒中等主要不良心脑血管事件及出血事件发生率。结果  替格瑞洛组在各时点的血小板高反应性发生率均低于氯吡格雷组,差异有统计学意义;替格瑞洛组较氯吡格雷组主要不良心脑血管事件发生率显著降低,差异有统计学意义 (5.2% vs. 11.7%,HR=0.412,95%CI为0.193~0.878,P=0.022);替格瑞洛组出血事件发生率高于氯吡格雷组,但差异无统计学意义。结论  低剂量替格瑞洛抗血小板方案可以降低SCAD患者主要不良心脑血管事件发生率。

关 键 词:替格瑞洛  氯吡格雷  低剂量  稳定型冠心病
收稿时间:2015-05-27

Efficacy and safety of low-dose ticagrelor in patients with stable coronary artery disease
LI Kang-bo,LIU Xiao-kun,ZHANG Qi,HAN Quan-le. Efficacy and safety of low-dose ticagrelor in patients with stable coronary artery disease[J]. Fudan University Journal of Medical Sciences, 2016, 43(2): 164. DOI: 10.3969/j.issn.1672-8467.2016.02.007
Authors:LI Kang-bo  LIU Xiao-kun  ZHANG Qi  HAN Quan-le
Affiliation:Department of Cardiology,Tangshan Worker′s Hospital,North China University of Science and Technology,Tangshan 063000,Hebei Province,China
Abstract:Objective  To evaluate the efficacy and safety of low-dose ticagrelor in patients with stable coronary artery disease. Methods  In the randomized,parallel designed clinical trial,413 patients with stable coronary artery disease were assigned to receive either ticagrelor 60 mg twice daily or clopidogrel 50 mg once daily for 12 months (all were given aspirin 100 mg once daily).Platelet function were serially measured at various time points by 3 assessment methods.The main adverse cardiovascular and cerebrovascular events (cardiovascular death,nonfatal myocardial infarction and stroke) and bleeding events were evaluated. Results  Patients with high on-treatment platelet reactivity (HPR) was fewer in ticagrelor group compared with clopidogrel group at various time points.The main adverse cardiovascular and cerebrovascular events occurred in fewer patients in ticagrelor group than in clopidogrel group (5.2% vs. 11.7%,HR=0.412,95%CI:0.193-0.878,P=0.022).There was no statistical difference in the rate of bleeding events between clopidogrel and ticagrelor groups. Conclusions  For patients with stable coronary artery disease,low-dose ticagrelor reduced cardiovascular and cerebrovascular events than low-dose clopidogrel.
Keywords:ticagrelor  clopidogrel  low-dose  stable coronary artery disease
点击此处可从《复旦学报(医学版)》浏览原始摘要信息
点击此处可从《复旦学报(医学版)》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号